AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Biznews9d
🔒 Novo’s insulin pen phase-out sparks CompCom probe as diabetes remains a silent killer among SA women
South Africa's Competition Commission investigates Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market.
Novo Nordisk, Sanofi face SA insulin antitrust probe
After a decade of being the primary supplier of human insulin pens in South Africa, Novo decided against bidding for the 2024 ...
Medical Marketing & Media6d
Novo Nordisk welcomes patients to the Ozempic Era
With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.
The Pharma Letter3d
Novo Nordisk releases new data on CagriSema
Danish diabetes and obesity giant Novo Nordisk (NOV: N) today announced headline results from REDEFINE 2, a Phase III trial ...
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...
BioSpace8d
Novo, Sanofi Hit With Anti-Competitive Probe in South Africa: Bloomberg
The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...